GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » Research & Development

Genetron Holdings (Genetron Holdings) Research & Development : $44.82 Mil (TTM As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Genetron Holdings's Research & Development for the three months ended in Jun. 2022 was $9.21 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2022 was $44.82 Mil.

Genetron Holdings Research & Development Historical Data

The historical data trend for Genetron Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetron Holdings Research & Development Chart

Genetron Holdings Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial 10.37 13.07 22.79 39.87 41.64

Genetron Holdings Quarterly Data
Dec17 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.66 13.42 12.54 9.21 -

Genetron Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $44.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetron Holdings  (NAS:GTH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Genetron Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Genetron Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetron Holdings (Genetron Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » Research & Development
Comparable Companies
BNR BDSX FONR PRPH ENZ LAB PRE VNRX SERA BIOQ TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
N/A
Address
No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206
Website
https://www.genetronhealth.com
Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.